Merck Procedure on Access to Clinical Trial Data

Overview
Merck (MSD outside US and Canada) is fully committed to supporting the EFPIA and PhRMA guiding principles on data sharing, including the principle of providing qualified scientific researchers access to anonymized patient-level data and full clinical study reports (CSRs) from Merck’s clinical trials to conduct legitimate scientific research. We are also fully participating in the Institutes of Medicine (IOM) global effort to develop principles for responsible sharing of clinical trial data.

Eligibility
Qualified researchers with appropriate competencies, engaged in rigorous, independent scientific research can submit a data request, for patient-level data or a full CSR, with a research proposal to Merck for review and will be asked to sign a data-sharing agreement prior to receiving access to clinical trial data. The research team must include a biostatistician.

• Conflict of interest will be assessed; data will not be released to individuals with significant conflict of interest or individuals requesting data access for competitive, commercial or legal interests.
• Funding requests are not supported under this procedure.

Application Process
Research proposals must be submitted through the website at http://engagezone.msd.com/ds_documentation.php and must adhere to the requirements for the submission process. The following basic information will be required:

1) Detailed Research proposal which includes:
   • Background and rationale
   • Objectives of the research
   • Scientific Hypothesis
   • Statistical analysis plan
   • Publication Plan

2) Curricula Vitae of all researchers including the biostatistician

Scope of Data
Merck will provide access to patient-level data and CSRs regarding clinical trials performed by Merck for which results are posted on clinicaltrials.gov registry (dating back to September 2007) for products or indications that have been approved by regulators in the US and EU. In general, data will be made available for request approximately 18 months after clinical trial completion and acceptance of primary results manuscript. Data from phase I trials in healthy volunteers and consumer health care studies are out of scope from this procedure.
There are additional circumstances that may prevent Merck from sharing the requested data:

- Merck may not have the legal authority because the product was co-developed with a partner or obtained from an external partner under a contract that does not permit the disclosure.
- It may be difficult to ensure protection of the privacy and confidentiality of research participants. For example, small trials (e.g., with less than 50 participants) or studies of rare diseases may have too few participants to prevent re-identification of individuals.
- The informed consent may not allow for data sharing.
- There may be substantial practical constraints to providing access to the data (for example, size and complexity of databases or resources required to retrieve data from repositories and redact personally identifiable information from relevant documents).

**Review Process**

Completed applications will be reviewed by Merck with input as needed from an External Scientific Review Board (ESRB) comprised of non-Merck scientists or physicians. Additional details on the governance of the board can be found in the ESRB Charter. Researchers will receive an acknowledgement of receipt and the request will be evaluated by an internal Merck review committee made up of subject matter experts in the relevant therapeutic area.

Once the request is assessed for feasibility, the Merck review committee will assess the scientific validity of the request and the qualifications of the requesters. If the Merck review committee determines that the request is scientifically valid and the requesters have the appropriate expertise to perform the proposed analysis then the request will be approved and data will be shared.

If there are questions or concerns regarding the scientific validity of a data request from the Merck review committee, the request will be forwarded to the External Scientific Review Board for further review. A recommendation from the ESRB will be communicated to a Merck Steering Committee, which is comprised of the research heads of clinical, regulatory, and biostatistics. The Merck Steering Committee will make the final decision on the data request after consideration of the recommendation from the ESRB.

Merck will communicate a formal notification of the status and the rationale to the researcher.

**Review Criteria**

- Does the proposal contain a clearly defined research question, scientific rationale and relevance of the proposed research to medical science or patient care?
- Is there a well-documented statistical analysis plan?
- Is there an ability of the proposed research plan (design, methods and analysis) to meet the scientific objectives?
- Is there an adequate publication plan for the dissemination of the research?
- Is the research applicant willing to disclose any real or potential conflicts of interest that may impact the planning, conduct or interpretation of the research?
- Does the research team have the expertise, qualifications and experience to conduct the proposed research (e.g., does it include a biostatistician as part of the research team)?
Data Sharing Agreement
Prior to access to clinical trial data, the researcher must enter into a standard data sharing agreement with Merck. The data sharing agreement commits the researcher to use the data only for the stated research purposes and not to disclose the data to third parties. This is in line with data privacy legislation. In addition, researchers are expected to commit to transparency in the publication of their work.

Anonymization of Data
Protecting the privacy of patients who participate in clinical trials is an important obligation of sponsors who conduct clinical trials and therefore Merck will take appropriate measures, including anonymization of data, to ensure that patient privacy is safeguarded.

Data Access
Merck will provide researchers with access to anonymized patient-level data needed to address the specific research question consistent with the requirements noted here.

If a request for a full CSR is approved, Merck will provide researchers the CSR in a redacted form that is consistent with the need to protect patient privacy and confidential commercial information.

An Evolving Procedure
Data sharing principles and processes are evolving and the procedure outlined here is intended as an initial step, subject to updates as appropriate based on Merck’s experience and the recommendations of advisory groups evaluating this issue such as the Institutes of Medicine, regulators, other members of industry, academic institutions and publishers.

Reviewed: January 2017